AzTrials
AzTrials

Quality of LifeNCT04676984

Medication Use and Quality of Life Among Older People (Pilot)

A study testing Consultations in people with Quality of Life and Reduction, Harm, run by Odense University Hospital at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This project will provide new evidence on how to optimize medication use among older people with limited life expectancy. This will be done by testing whether a patient-centered deprescribing intervention, focused on aligning medical treatment with patients' preferences, can improve quality of life among older people… Read more about this study

Who is it for?
Ages 80 years and older
Conditions the study is for
Quality of Life, Reduction, Harm
What is being tested?
Consultations
Could I receive a placebo?
No, everyone receives an active treatment
How many people
3 participants
Where
1 siteDenmark
Study dates
1 Jun 2020to 8 Jul 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 80 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Aged ≥80 years
  • Take ≥8 different medications
  • Have a life expectancy of <2 years, estimated via the Surprise Question ("Would you be surprised if this patient died within 1-2 years?") by the general practitioner
  • Have a Mini-Mental State Exam (MMSE) score of ≥15
  • Are able to provide informed consent

Who cannot join

  • Not able to communicate
  • Does not speak and understand Danish

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Odense University Hospital

    Odense, Region Syddanmark, 5000

Other trials in Denmark

About this study

This project will provide new evidence on how to optimize medication use among older people with limited life expectancy. This will be done by testing whether a patient-centered deprescribing intervention, focused on aligning medical treatment with patients' preferences, can improve quality of life among older people with limited life expectancy. This registration concerns the initial pilot study.

Read the detailed description

In a pragmatic randomized controlled trial, this project will test whether a comprehensive and patient-centered deprescribing intervention can improve quality of life among older people with limited life expectancy. This registration concerns the initial pilot study. All patients included in the pilot study will receive the intervention (that is, the pilot study will not include randomization).

The intervention will comprise a series of consultations between the patient and general practitioner (GP) (at least three) to continuously adjust the patient's medication according to the patient's goals, needs, and preferences, thereby ensuring alignment with the patient's priorities. Thus, the purpose of this intervention is to initiate and facilitate a continued deprescribing process. The process can be summarized in seven steps: During an initial consultation (1: Consultation 0), the GP assesses patient eligibility. If the patient would like to participate, a project nurse subsequently visits the patient at home (2: Home visit) for retrieval of informed consent as well as baseline measurements. During the next consultation (3: Consultation 1), the patient and GP discuss how the patient feels about his/her medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation. The patients prepares (4: Preparation) by considering and verbalizing his/her goals of care and treatment preferences. Simultaneously, a clinical pharmacist examines the patient's medication list and provides suggestions to the GP on which drugs can be continued and deprescribed, respectively. During the next consultation (5: Consultation 2), the patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities. During a new consultation (6: Consultation 3), the patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (7: Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal.

Being tested
Consultations
Keywords
Deprescribing, Polypharmacy, Guideline
Medical subject headings
Harm Reduction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ConsultationsOther

    The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.

Study groups in NCT04676984
Study groupRoleWhat they receive
ConsultationsOtherThe intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
Receives: Other: Consultations

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HEALTH-RELATED QUALITY OF LIFE

    Health-related quality of life will be measured using the Danish version of the SF-12v2 Health Survey.

    Measured: Baseline

  2. CHANGE FROM BASELINE HEALTH-RELATED QUALITY OF LIFE AT 3 MONTHS

    Health-related quality of life will be measured using the Danish version of the SF-12v2 Health Survey.

    Measured: 3 months

  3. CHANGE FROM BASELINE HEALTH-RELATED QUALITY OF LIFE AT 6 MONTHS

    Health-related quality of life will be measured using the Danish version of the SF-12v2 Health Survey.

    Measured: 6 months

  4. HEALTH-RELATED QUALITY OF LIFE (DEPRESSION)

    Health-related quality of life will be measured using the Danish version of the Depression List.

    Measured: Baseline

  5. CHANGE FROM BASELINE HEALTH-RELATED QUALITY OF LIFE (DEPRESSION) AT 3 MONTHS

    Health-related quality of life will be measured using the Danish version of the Depression List.

    Measured: 3 months

  6. CHANGE FROM BASELINE HEALTH-RELATED QUALITY OF LIFE (DEPRESSION) AT 6 MONTHS

    Health-related quality of life will be measured using the Danish version of the Depression List.

    Measured: 6 months

  7. MORTALITY

    Mortality will be assessed through the nationwide Danish Central Person Registry.

    Measured: 3 months

  8. MORTALITY

    Mortality will be assessed through the nationwide Danish Central Person Registry.

    Measured: 6 months

  9. MORTALITY

    Mortality will be assessed through the nationwide Danish Central Person Registry.

    Measured: 12 months

Secondary outcomes (9)
  1. COGNITIVE FUNCTION

    Cognitive function will be measured using the Danish version of the Mini-Mental State Examination-2 (MMSE-2) Standard Form.

    Measured: Baseline, 3 months and 6 months

  2. FUNCTIONAL LEVEL

    Functional level will be measured using the Danish version of the Vulnerable Elders Survey 13 (VES-13).

    Measured: Baseline, 3 months and 6 months

  3. HAND-GRIP STRENGTH

    Hand-grip strength will be measured using a hand-grip dynamometer.

    Measured: Baseline, 3 months and 6 months

  4. ABILITY TO SIT AND STAND

    Ability to sit and stand will be measured via the 30-second stand-sit-test.

    Measured: Baseline, 3 months and 6 months

  5. NUMBER OF MEDICATIONS DISCONTINUED

    Number of medications dicontinued will be assessed through the medication lists.

    Measured: 3 months, 6 months and 12 months

  6. NUMBER OF MEDICATION CHANGES

    Number of medication changes will be assessed through the medication lists.

    Measured: 3 months, 6 months and 12 months

  7. HOSPITAL ADMISSIONS

    Admissions will be assessed through the nationwide Danish National Patient Register.

    Measured: 3 months, 6 months and 12 months

  8. HEALTH CARE COSTS

    Health care costs.

    Measured: 3 months, 6 months and 12 months

  9. SUCCESS RATE OF THE INTERVENTION

    Succes rate of the intervention.

    Measured: 3 months, 6 months and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Dec 2020
  2. Study start1 Jun 2020
  3. Primary completion12 Apr 2021
  4. Study completion8 Jul 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
3 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04676984
Sponsor's protocol ID
ODIN-1 Pilot
Status last verified
Apr 2022
First submitted
1 Dec 2020
Last updated
26 Apr 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Consultations in people with Quality of Life and Reduction, Harm, run by Odense University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HEALTH-RELATED QUALITY OF LIFE (time frame: Baseline). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in